Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | APLT |
---|---|---|
09:32 ET | 14012 | 4.22 |
09:34 ET | 100 | 4.18 |
09:36 ET | 100 | 4.2198 |
09:38 ET | 11079 | 4.23 |
09:39 ET | 2102 | 4.24 |
09:41 ET | 4442 | 4.29 |
09:43 ET | 6035 | 4.31 |
09:45 ET | 1000 | 4.3 |
09:48 ET | 100 | 4.29 |
09:50 ET | 1334 | 4.2801 |
09:52 ET | 3275 | 4.22 |
09:54 ET | 1100 | 4.22 |
09:56 ET | 21975 | 4.15 |
09:57 ET | 2832 | 4.13 |
09:59 ET | 8395 | 4.16 |
10:01 ET | 2627 | 4.15 |
10:03 ET | 3870 | 4.16 |
10:06 ET | 4696 | 4.15 |
10:08 ET | 3029 | 4.15 |
10:10 ET | 150 | 4.15 |
10:12 ET | 4750 | 4.14 |
10:14 ET | 10864 | 4.13 |
10:15 ET | 417 | 4.12 |
10:17 ET | 1418 | 4.1 |
10:19 ET | 6149 | 4.1 |
10:21 ET | 21888 | 4.11 |
10:24 ET | 4150 | 4.105 |
10:26 ET | 17578 | 4.105 |
10:28 ET | 2943 | 4.13 |
10:30 ET | 1530 | 4.12 |
10:32 ET | 5124 | 4.115 |
10:33 ET | 1965 | 4.14 |
10:35 ET | 2250 | 4.17 |
10:37 ET | 1493 | 4.165 |
10:42 ET | 10933 | 4.15 |
10:44 ET | 3911 | 4.16 |
10:46 ET | 12283 | 4.175 |
10:48 ET | 3719 | 4.165 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Applied Therapeutics Inc | 489.1M | -2.2x | --- |
Absci Corp | 476.1M | -3.9x | --- |
Fulcrum Therapeutics Inc | 487.9M | -5.2x | --- |
IGM Biosciences Inc | 491.7M | -1.9x | --- |
Verve Therapeutics Inc | 435.8M | -1.8x | --- |
Neurogene Inc | 488.1M | -8.2x | --- |
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $489.1M |
---|---|
Revenue (TTM) | $-477.0K |
Shares Outstanding | 114.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.89 |
EPS | $-1.91 |
Book Value | $-0.20 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.